vs
Mission Produce, Inc.（AVO）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Mission Produce, Inc.的季度营收约是Orthofix Medical Inc.的1.5倍（$319.0M vs $219.9M），Mission Produce, Inc.净利率更高（5.0% vs -1.0%，领先6.0%），Orthofix Medical Inc.同比增速更快（2.0% vs -10.0%），Mission Produce, Inc.自由现金流更多（$55.6M vs $16.8M），过去两年Mission Produce, Inc.的营收复合增速更高（11.0% vs 8.0%）
根据现有信息，该描述将Mission Produce, Inc.错误混淆为一家日本电子游戏企业。原描述提及这家企业由前IREM员工于1990年4月6日创立，曾为艾尼克斯、哈德森开发多款游戏，作品覆盖街机、超级任天堂、Nintendo 64、PlayStation等多个平台。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
AVO vs OFIX — 直观对比
营收规模更大
AVO
是对方的1.5倍
$219.9M
营收增速更快
OFIX
高出12.0%
-10.0%
净利率更高
AVO
高出6.0%
-1.0%
自由现金流更多
AVO
多$38.8M
$16.8M
两年增速更快
AVO
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $319.0M | $219.9M |
| 净利润 | $16.0M | $-2.2M |
| 毛利率 | 17.5% | 71.1% |
| 营业利润率 | 8.8% | 0.2% |
| 净利率 | 5.0% | -1.0% |
| 营收同比 | -10.0% | 2.0% |
| 净利润同比 | -7.5% | 92.4% |
| 每股收益（稀释后） | $0.23 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVOOFIX
| Q4 25 | $319.0M | $219.9M | ||
| Q3 25 | $357.7M | $205.6M | ||
| Q2 25 | $380.3M | $203.1M | ||
| Q1 25 | $334.2M | $193.6M | ||
| Q4 24 | $354.4M | $215.7M | ||
| Q3 24 | $324.0M | $196.6M | ||
| Q2 24 | $297.6M | $198.6M | ||
| Q1 24 | $258.7M | $188.6M |
净利润AVOOFIX
| Q4 25 | $16.0M | $-2.2M | ||
| Q3 25 | $14.7M | $-22.8M | ||
| Q2 25 | $3.1M | $-14.1M | ||
| Q1 25 | $3.9M | $-53.1M | ||
| Q4 24 | $17.3M | $-29.1M | ||
| Q3 24 | $12.4M | $-27.4M | ||
| Q2 24 | $7.0M | $-33.4M | ||
| Q1 24 | $0 | $-36.0M |
毛利率AVOOFIX
| Q4 25 | 17.5% | 71.1% | ||
| Q3 25 | 12.6% | 72.2% | ||
| Q2 25 | 7.5% | 68.7% | ||
| Q1 25 | 9.4% | 62.8% | ||
| Q4 24 | 15.7% | 69.0% | ||
| Q3 24 | 11.4% | 68.7% | ||
| Q2 24 | 10.4% | 67.8% | ||
| Q1 24 | 11.1% | 67.5% |
营业利润率AVOOFIX
| Q4 25 | 8.8% | 0.2% | ||
| Q3 25 | 5.9% | -8.3% | ||
| Q2 25 | 1.8% | -7.9% | ||
| Q1 25 | 2.8% | -25.2% | ||
| Q4 24 | 8.1% | -5.3% | ||
| Q3 24 | 5.2% | -9.6% | ||
| Q2 24 | 4.1% | -12.5% | ||
| Q1 24 | 3.1% | -15.6% |
净利率AVOOFIX
| Q4 25 | 5.0% | -1.0% | ||
| Q3 25 | 4.1% | -11.1% | ||
| Q2 25 | 0.8% | -6.9% | ||
| Q1 25 | 1.2% | -27.4% | ||
| Q4 24 | 4.9% | -13.5% | ||
| Q3 24 | 3.8% | -13.9% | ||
| Q2 24 | 2.4% | -16.8% | ||
| Q1 24 | — | -19.1% |
每股收益（稀释后）AVOOFIX
| Q4 25 | $0.23 | $-0.05 | ||
| Q3 25 | $0.21 | $-0.57 | ||
| Q2 25 | $0.04 | $-0.36 | ||
| Q1 25 | $0.05 | $-1.35 | ||
| Q4 24 | $0.25 | $-0.76 | ||
| Q3 24 | $0.17 | $-0.71 | ||
| Q2 24 | $0.10 | $-0.88 | ||
| Q1 24 | $0.00 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.8M | $82.0M |
| 总债务越低越好 | $95.8M | — |
| 股东权益账面价值 | $587.3M | $450.0M |
| 总资产 | $983.0M | $850.6M |
| 负债/权益比越低杠杆越低 | 0.16× | — |
8季度趋势，按日历期对齐
现金及短期投资AVOOFIX
| Q4 25 | $64.8M | $82.0M | ||
| Q3 25 | $43.7M | $62.9M | ||
| Q2 25 | $36.7M | $65.6M | ||
| Q1 25 | $40.1M | $58.0M | ||
| Q4 24 | $58.0M | $83.2M | ||
| Q3 24 | $49.5M | $30.1M | ||
| Q2 24 | $46.2M | $26.4M | ||
| Q1 24 | $39.9M | $27.0M |
总债务AVOOFIX
| Q4 25 | $95.8M | — | ||
| Q3 25 | $131.5M | $157.2M | ||
| Q2 25 | $147.2M | $157.0M | ||
| Q1 25 | $117.9M | $156.9M | ||
| Q4 24 | $113.7M | $157.0M | ||
| Q3 24 | $134.4M | $118.5M | ||
| Q2 24 | $170.2M | $118.0M | ||
| Q1 24 | $156.1M | $118.2M |
股东权益AVOOFIX
| Q4 25 | $587.3M | $450.0M | ||
| Q3 25 | $568.7M | $442.5M | ||
| Q2 25 | $552.3M | $458.3M | ||
| Q1 25 | $550.8M | $458.3M | ||
| Q4 24 | $547.3M | $503.1M | ||
| Q3 24 | $527.3M | $525.9M | ||
| Q2 24 | $513.3M | $546.0M | ||
| Q1 24 | $505.1M | $570.3M |
总资产AVOOFIX
| Q4 25 | $983.0M | $850.6M | ||
| Q3 25 | $1.0B | $832.6M | ||
| Q2 25 | $1.0B | $837.2M | ||
| Q1 25 | $997.8M | $823.1M | ||
| Q4 24 | $971.5M | $893.3M | ||
| Q3 24 | $959.9M | $867.9M | ||
| Q2 24 | $966.9M | $882.0M | ||
| Q1 24 | $937.5M | $906.0M |
负债/权益比AVOOFIX
| Q4 25 | 0.16× | — | ||
| Q3 25 | 0.23× | 0.36× | ||
| Q2 25 | 0.27× | 0.34× | ||
| Q1 25 | 0.21× | 0.34× | ||
| Q4 24 | 0.21× | 0.31× | ||
| Q3 24 | 0.25× | 0.23× | ||
| Q2 24 | 0.33× | 0.22× | ||
| Q1 24 | 0.31× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $67.2M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $55.6M | $16.8M |
| 自由现金流率自由现金流/营收 | 17.4% | 7.6% |
| 资本支出强度资本支出/营收 | 3.6% | 4.9% |
| 现金转化率经营现金流/净利润 | 4.20× | — |
| 过去12个月自由现金流最近4个季度 | $37.2M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流AVOOFIX
| Q4 25 | $67.2M | $27.7M | ||
| Q3 25 | $34.4M | $12.4M | ||
| Q2 25 | $-11.8M | $11.6M | ||
| Q1 25 | $-1.2M | $-18.4M | ||
| Q4 24 | $38.0M | $23.7M | ||
| Q3 24 | $42.5M | $11.7M | ||
| Q2 24 | $3.4M | $9.0M | ||
| Q1 24 | $9.5M | $-18.6M |
自由现金流AVOOFIX
| Q4 25 | $55.6M | $16.8M | ||
| Q3 25 | $22.6M | $2.5M | ||
| Q2 25 | $-25.0M | $4.5M | ||
| Q1 25 | $-16.0M | $-25.1M | ||
| Q4 24 | $31.1M | $15.2M | ||
| Q3 24 | $34.9M | $6.3M | ||
| Q2 24 | $-4.4M | $-360.0K | ||
| Q1 24 | $-400.0K | $-29.1M |
自由现金流率AVOOFIX
| Q4 25 | 17.4% | 7.6% | ||
| Q3 25 | 6.3% | 1.2% | ||
| Q2 25 | -6.6% | 2.2% | ||
| Q1 25 | -4.8% | -13.0% | ||
| Q4 24 | 8.8% | 7.0% | ||
| Q3 24 | 10.8% | 3.2% | ||
| Q2 24 | -1.5% | -0.2% | ||
| Q1 24 | -0.2% | -15.4% |
资本支出强度AVOOFIX
| Q4 25 | 3.6% | 4.9% | ||
| Q3 25 | 3.3% | 4.8% | ||
| Q2 25 | 3.5% | 3.5% | ||
| Q1 25 | 4.4% | 3.5% | ||
| Q4 24 | 1.9% | 4.0% | ||
| Q3 24 | 2.3% | 2.7% | ||
| Q2 24 | 2.6% | 4.7% | ||
| Q1 24 | 3.8% | 5.6% |
现金转化率AVOOFIX
| Q4 25 | 4.20× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | -3.81× | — | ||
| Q1 25 | -0.31× | — | ||
| Q4 24 | 2.20× | — | ||
| Q3 24 | 3.43× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVO
| Avocado | $256.9M | 81% |
| Blueberry | $36.5M | 11% |
| Mango | $18.7M | 6% |
| Other | $6.9M | 2% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
